Clinical Trials

Study Title

A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (3000-03-005/ENGOT-OV44)

Purpose

To compare the progression-free survival (PFS) of patients with Stage III or IV ovarian cancer treated with platinum-based therapy, TSR-042, and niraparib to standard-of-care (SOC) platinum-based therapy.

Eligibility

Study Process